Philip Morris International Inc. reports developments across its cigarette business and expanding smoke-free portfolio, including IQOS heated tobacco products, ZYN nicotine pouches and e-vapor offerings. Company news commonly covers quarterly results, shipment and revenue trends, product authorizations, brand collaborations, and updates tied to adult-smoker alternatives.
Recurring announcements also address U.S. and international regulatory matters, including FDA modified-risk tobacco product authorizations for IQOS, as well as annual shareholder meetings, board elections, executive compensation votes, auditor ratification, shareholder proposals, and corporate responsibility initiatives.
Philip Morris International Inc. (NYSE:PM) CFO Emmanuel Babeau addressed investors at the Morgan Stanley Virtual Global Consumer & Retail Conference. He revised the full-year 2020 reported diluted EPS forecast to approximately $5.08, slightly up from the previous range of $5.03 to $5.08. This revision reflects lower costs due to efficiencies and pandemic-related adjustments. The forecast suggests a 6% increase from the pro forma adjusted diluted EPS of $5.13 in 2019. Key assumptions include HTU shipment volumes of 75 to 76 billion units and market share gains in IQOS geographies.
Philip Morris International (PM) will hold a live video webcast featuring CFO Emmanuel Babeau at the Morgan Stanley Virtual Global Consumer & Retail Conference on December 2, 2020, starting at 10:00 a.m. ET. The session will be accessible via www.pmi.com/2020morganstanley, where presentation slides will also be available. An archived version of the webcast will remain online until December 31, 2020. PMI is committed to transitioning to a smoke-free future, with around 11.7 million adult smokers switching to its heat-not-burn product as of September 30, 2020.
Summary not available.
Philip Morris Investments B.V., a subsidiary of Philip Morris International (PM), holds a one-third stake in Medicago, focusing on plant-derived vaccine development. Medicago has secured a deal with the Canadian government to supply 76 million doses of its COVID-19 vaccine, with C$173M ($131M) funding for its trials and manufacturing. PMI's CEO praised the collaboration to accelerate vaccine development. Medicago is currently advancing through clinical trials, with Phase 1 testing completed on July 14, and anticipates Phase 2 trials to start in November 2020.
Philip Morris International Inc. (NYSE:PM) reported its 2020 third-quarter results, highlighting a reported diluted EPS of $1.48, up 21.3%. Adjusted diluted EPS decreased by 0.7% to $1.42, while organic growth showed a 5.6% increase. Cigarette and heated tobacco volume shipments fell by 7.6%, but IQOS market share rose to 6.0%. Net revenues declined 2.6%, and operating income increased by 16.3%. The company raised its full-year diluted EPS guidance to $5.03-$5.08, driven by improved industry volumes and favorable tax effects. PMI assured no significant supply disruptions amid COVID-19.
Philip Morris International (NYSE: PM) will host a live audio webcast on October 20, 2020, at 9:00 a.m. ET to discuss its 2020 Third-Quarter results, which will be released at 7:00 a.m. ET the same day. CFO Emmanuel Babeau will provide insights and answer questions during the session, which will be accessible in listen-only mode. Investors can also access the webcast via PMI's Investor Relations Mobile App. The archived version will be available until November 18, 2020. PMI is transforming the tobacco industry, focusing on smoke-free products and aims to replace traditional cigarettes with healthier alternatives.
Summary not available.